FibroBiologics has commenced patient dosing in a Phase 1/2 trial for CYWC628, targeting diabetic foot ulcers.
Quiver AI Summary
FibroBiologics, Inc., a clinical-stage biotechnology company focused on developing therapies for chronic diseases using fibroblasts, has announced the initiation of patient dosing in its Phase 1/2 clinical trial for CYWC628, a treatment for diabetic foot ulcers. This initial dosing occurred the week of June 1, 2026, while the company simultaneously advances its manufacturing processes for CYWC628, including shipping drug product from its second GMP run to Australia. The CEO, Pete O'Heeron, emphasized the significance of transitioning their research into real-world applications, noting that CYWC628 aims to restore the biology of chronic wounds rather than merely addressing symptoms. The company has demonstrated consistent manufacturing capabilities, which it views as crucial for supporting its ongoing clinical trials and future scaling. The investigational therapy is designed to expedite wound healing based on promising preclinical data.
Potential Positives
- Successful initiation of Phase 1/2 clinical trial for CYWC628, indicating progress in the development of a potential treatment for diabetic foot ulcers.
- Completion and release of drug product from the second GMP manufacturing run, demonstrating adequate supply chain management for clinical activities.
- Manufacturing of first two batches of the third GMP run has been completed, indicating readiness to support ongoing clinical trials and future scaling.
- Possibility of CYWC628 significantly accelerating wound healing based on preclinical data could position FibroBiologics as a leader in innovative wound care solutions.
Potential Negatives
- Potential risks related to liquidity and capital resources, which may impact the company's ability to conduct its business effectively.
- Forward-looking statements indicate uncertainties regarding the success of ongoing clinical trials and the eventual outcomes, suggesting a lack of guaranteed performance.
- Concerns over the unpredictable relationship between preclinical results and clinical study outcomes may undermine investor confidence in the company's future prospects.
FAQ
What is CYWC628?
CYWC628 is an investigational fibroblast cell-based therapy for accelerating wound healing, particularly in diabetic foot ulcers.
When did FibroBiologics start dosing patients for their clinical trial?
The first patients were dosed during the week of June 1, 2026, in a Phase 1/2 clinical trial.
What is the purpose of the Phase 1/2 clinical trial?
The trial evaluates the safety, tolerability, and efficacy of CYWC628 for treating refractory diabetic foot ulcers.
How many patents does FibroBiologics hold?
FibroBiologics has more than 270 patents issued and pending related to their therapeutic developments.
Where can I find more information about FibroBiologics?
More information can be found on FibroBiologics' website or by contacting them via email or social media.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$FBLG Insider Trading Activity
$FBLG insiders have traded $FBLG stock on the open market 6 times in the past 6 months. Of those trades, 6 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $FBLG stock by insiders over the last 6 months:
- JASON DAVIS (Chief Financial Officer) purchased 70,000 shares for an estimated $28,973
- PETE O'HEERON (CHIEF EXECUTIVE OFFICER) has made 3 purchases buying 51,500 shares for an estimated $19,530 and 0 sales.
- RUBEN A GARCIA (General Counsel) purchased 40,000 shares for an estimated $13,056
- HAMID KHOJA (Chief Scientific Officer) purchased 30,000 shares for an estimated $11,400
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$FBLG Hedge Fund Activity
We have seen 2 institutional investors add shares of $FBLG stock to their portfolio, and 57 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- YORKVILLE ADVISORS GLOBAL, LP removed 509,787 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $114,651
- BLACKROCK, INC. removed 457,754 shares (-94.9%) from their portfolio in Q1 2026, for an estimated $604,235
- GEODE CAPITAL MANAGEMENT, LLC removed 319,152 shares (-91.5%) from their portfolio in Q1 2026, for an estimated $421,280
- GTS SECURITIES LLC removed 308,661 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $69,417
- RENAISSANCE TECHNOLOGIES LLC removed 215,603 shares (-93.1%) from their portfolio in Q1 2026, for an estimated $284,595
- JANE STREET GROUP, LLC removed 149,763 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $197,687
- AMG NATIONAL TRUST BANK removed 138,960 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $183,427
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$FBLG Analyst Ratings
Wall Street analysts have issued reports on $FBLG in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 01/02/2026
To track analyst ratings and price targets for $FBLG, check out Quiver Quantitative's $FBLG forecast page.
$FBLG Price Targets
Multiple analysts have issued price targets for $FBLG recently. We have seen 2 analysts offer price targets for $FBLG in the last 6 months, with a median target of $7.5.
Here are some recent targets:
- Matthew Caufield from HC Wainwright & Co. set a target price of $8.0 on 04/16/2026
- Jason Kolbert from D. Boral Capital set a target price of $7.0 on 03/12/2026
Full Release
HOUSTON, June 16, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that the first patients have been dosed in the Company’s Phase 1/2 clinical trial evaluating CYWC628 for the treatment of diabetic foot ulcers (DFUs). Initial dosing took place during the week of June 1, 2026.
In parallel with clinical progress, FibroBiologics continues to advance manufacturing of CYWC628 to support ongoing trial activity. Drug product from the Company's second good manufacturing practice (GMP) manufacturing run has been released and is scheduled to ship to Australia during the week of June 15, 2026. FibroBiologics has also completed the manufacturing of the first two batches of its third GMP manufacturing run.
“Initiating treatment in our first patients marks the moment our science transitions from the laboratory into the lives of the people in need,” said Pete O'Heeron, Founder and Chief Executive Officer of FibroBiologics. “Fibroblasts are the body's own architects of repair, and CYWC628 is designed to restore the underlying biology that chronic wounds have lost rather than managing symptoms. Successfully advancing our clinical and manufacturing operations in parallel reflects the disciplined execution we set out to deliver.”
“Producing consecutive GMP runs of CYWC628 demonstrates that our fibroblast manufacturing platform is reproducible and ready to supply the ongoing clinical trial and beyond,” said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. “This consistency is foundational. It provides us confidence both in the integrity of the product reaching patients and our ability to scale for clinical use.”
For more information, please visit FibroBiologics' website , email FibroBiologics at [email protected] or follow FibroBiologics on LinkedIn , YouTube , Facebook or X .
About CYWC628
CYWC628 is an investigational topically administered allogeneic fibroblast cell-based therapy for wound healing. Preclinical data suggest CYWC628 may significantly accelerate wound healing compared to currently available treatments.
FibroBiologics is conducting a prospective, multicenter, randomized clinical trial evaluating the safety, tolerability, and efficacy of CYWC628 in treating refractory diabetic foot ulcers with up to 12 weeks of treatment using either standard of care plus a low or high-dose of CYWC628, or standard of care only.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit
www.FibroBiologics.com
.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning FibroBiologics’ clinical trials and research and development programs, and the potential clinical benefits of fibroblasts and fibroblast-derived materials. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption “Risk Factors” and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of FibroBiologics’ R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; (d) the ability of FibroBiologics to successfully prosecute its patent applications, (e) FibroBiologics’ ability to manufacture its product candidates; and (f) FibroBiologics’ ability to conduct clinical trials. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
General Inquiries:
[email protected]
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
[email protected]
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
[email protected]
